Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is ruxotemitide, an oncolytic molecule that is developed for intratumoral injections, which is in Phase III clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma; and NeoLIPA Phase II study in combination with pembrolizumab. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a partnership with Verrica Pharmaceuticals Inc. for the development and commercialization of ruxotemitide for the treatment of all malignant and pre-malignant dermatological indications. Lytix Biopharma ASA was founded in 2003 and is based in Oslo, Norway.…
Lytix Biopharma ASA - Mandatory notification of trade by close associates to primary insiders
Lytix Biopharma (OSL: LYTIX) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 14 employees.
The shares were at 8.000 NOK on 20 November 2026, down 23.4% over 52 weeks. Its 52-week range is 7.240 NOK to 11.90 NOK: the price is 32.8% below the high and 10.5% above the low.
Its market capitalisation is 615.20M NOK.
Lytix Biopharma reports return on equity of -97.1% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 89.62M NOK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock; their mean price target of 15.50 NOK is 93.8% above the current price. The next earnings report is expected on 11 February 2027.